Curevac AG

Generelle oplysninger

Founded in 2000 as a spin-off from the University of Tϋbingen in Germany, CureVac is a technology leader in the development of drugs that are based on Messenger RNA (mRNA). The company has more than 17 years of expertise in handling, optimizing and manufacturing this versatile molecule for medical purposes.
The basic principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases.
CureVac has entered into various collaborations with multinational corporations and organizations, including agreements with Lilly, Boehringer Ingelheim, Sanofi Pasteur and the Bill & Melinda Gates Foundation.
In 2006, CureVac successfully established the first GMP facility worldwide for the manufacturing of mRNA. In 2017 CureVac started the construction of an industrial scale production facility.